Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Cost of revenue (excluding amortization and depreciation) | 14,725 | 9,789 |
| Research and development | 52,677 | 44,785 |
| Selling, general and administrative | 184,996 | 120,787 |
| Loss in fair value of contingent consideration | 590 | 1,512 |
| Intangible asset amortization | 1,572 | 1,572 |
| Total operating expenses | 254,560 | 178,445 |
| Loss from operations | (63,357) | (56,982) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's SG&A?
- Axsome Therapeutics (AXSM) reported SG&A of $185M in Q1 2026.
- How has Axsome Therapeutics's SG&A changed year-over-year?
- Axsome Therapeutics's SG&A increased by 53.2% year-over-year, from $120.79M to $185M.
- What is the long-term trend for Axsome Therapeutics's SG&A?
- Over 4 years (2021 to 2025), Axsome Therapeutics's SG&A has grown at a 71.1% compound annual growth rate (CAGR), from $66.65M to $570.6M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Axsome Therapeutics's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude